Viewpoint News & Awards

Market for Nuclear Medicine Therapies Poised for Growth

Will Xofigo be the first nuclear medicine blockbuster?

A recent post on DOTMed describes an emerging market for therapeutic radiopharmaceuticals and a solid market for diagnostic radiopharmaceuticals that is expected to fuel average annual growth of 11% in the global nuclear medicine market, according to a MEDraysintell report. Xofigo from Bayer — used to treat prostate and bone cancers — is poised to be the “first blockbuster of nuclear medicine,” fueling major growth in that area, and gallium-68 looks promising for use with PET diagnostic procedures. The report also projects resolution to molybdenum supply issues and notes that support from mainstream pharma is needed to continue development of nuclear medicine.

Find out more: